Faruqi & Faruqi Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Merck & Co., Inc. related to misleading statements about Gardasil sales and is encouraging affected investors to participate in a federal securities class action [2][4]. Group 1: Legal Investigation and Class Action - The law firm is urging investors who suffered losses exceeding $100,000 in Merck between February 3, 2022, and February 3, 2025, to contact them for legal options [1]. - There is an April 14, 2025, deadline for investors to seek the role of lead plaintiff in the class action against Merck [2]. - The complaint alleges that Merck and its executives violated federal securities laws by making false statements regarding Gardasil's expected revenue and demand in China [4]. Group 2: Financial Performance and Market Reaction - Merck reported a 3% decline in GARDASIL/GARDASIL 9 sales, totaling $8.6 billion for the fourth quarter and full year of 2024 [5]. - Following the announcement of the sales decline and a decision to pause shipments of Gardasil into China, Merck's stock price dropped by $9.05 per share, or 9.1%, closing at $90.74 on February 4, 2025 [6].